Limits...
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients.

Long L, Shen T, Gao J, Duan Z, Liang H, Lu F - BMC Infect. Dis. (2014)

Bottom Line: Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012).An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study.Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.

View Article: PubMed Central - PubMed

ABSTRACT

Background: The measurement of hepatitis C virus core antigen (HCV-coreAg) has been shown to be an indicator of active HCV infection. The aim of the present study was 1) to investigate the stability and effectiveness of HCV-coreAg and HCV-RNA quantification in HCV infection with or without HIV-1 coinfection, 2) to explore the association between the HCV-coreAg/HCV-RNA (Ag/RNA) ratio and the immune status in chronic HCV/HIV-1-coinfected patients.

Methods: A longitudinal investigation comprised of 227 HCV-monoinfected (n = 129) and HCV/HIV-1-coinfected (n = 98) patients was initiated in August 2009, and 139 (73 with HCV monoinfection and 66 with HCV/HIV-1 coinfection) were followed up in August 2012. Both HCV core antigen and HCV RNA quantification were determined on this cryopreserved plasma. HCV core antigen and HCV RNA quantification were performed subsequently. In addition, an in vitro experiment investigating the possibility of degradation of HCV components (core antigen and RNA) were conducted.

Results: Significant and stable correlations (p < 0.001) were observed both in chronic HCV-monoinfected and HCV/HIV-1-coinfected patients over the 3-year observation. Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012). Moreover, the Ag/RNA ratios were negatively correlated with CD4+ T-cell counts (p < 0.001). An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study.

Conclusions: Our longitudinal study indicated that the HCV-coreAg presented comparable dynamics over time as HCV RNA in chronic HCV-infected patients. Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.

Show MeSH

Related in: MedlinePlus

In vitrohepatitis C virus particle degradation experiment. Changes in the degradation dynamics of HCV-RNA and HCV- coreAg, (A) in medium, HIV-1-positive, and healthy plasma after incubation at 37°C for 12 hours. The X axis indicates the degradation of HCV-RNA or HCV-coreAg at 12 hours, expressed as a percentage of the initial levels. (B) HCV-coreAg/HCV-RNA ratios at 12 hours in HIV-1-positive plasma were significantly higher than those in healthy plasma. Unpaired t tests and Mann–Whitney U-tests were performed, p < 0.05 indicates significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4225041&req=5

Fig4: In vitrohepatitis C virus particle degradation experiment. Changes in the degradation dynamics of HCV-RNA and HCV- coreAg, (A) in medium, HIV-1-positive, and healthy plasma after incubation at 37°C for 12 hours. The X axis indicates the degradation of HCV-RNA or HCV-coreAg at 12 hours, expressed as a percentage of the initial levels. (B) HCV-coreAg/HCV-RNA ratios at 12 hours in HIV-1-positive plasma were significantly higher than those in healthy plasma. Unpaired t tests and Mann–Whitney U-tests were performed, p < 0.05 indicates significance.

Mentions: After incubating at 37°C for 12 hours, the average HCV-RNA levels decreased to 33.49%, 54.92%, and 73.16% of the initial levels in medium, healthy plasma, and HIV-1-positive plasma, respectively, whereas at the same time, the average HCV-coreAg levels decreased to 9.16%, 46.16%, and 42.45% of the initial levels. Decay rates of HCV-RNA and HCV-coreAg at 12 hours were significantly lower in medium than in healthy plasma (HCV-RNA: p < 0.001, HCV-coreAg: p < 0.001) and in HIV-1-positive plasma (HCV-RNA: p < 0.001, HCV-coreAg: p < 0.001) (Figure 4A). The decay rate of HCV-RNA in healthy plasma was significantly lower than in HIV-1-positive plasma (p = 0.035), while no similar difference was observed in the decay of HCV-coreAg (p > 0.05). Further, we observed that the Ag/RNA ratios in HIV-1-positive plasma were significantly higher than in healthy plasma (p = 0.005, Figure 4B). Certainly, it must be noted that the influence of blood cells on degradation of HCV is not addressed in this in vitro experiment.Figure 4


Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients.

Long L, Shen T, Gao J, Duan Z, Liang H, Lu F - BMC Infect. Dis. (2014)

In vitrohepatitis C virus particle degradation experiment. Changes in the degradation dynamics of HCV-RNA and HCV- coreAg, (A) in medium, HIV-1-positive, and healthy plasma after incubation at 37°C for 12 hours. The X axis indicates the degradation of HCV-RNA or HCV-coreAg at 12 hours, expressed as a percentage of the initial levels. (B) HCV-coreAg/HCV-RNA ratios at 12 hours in HIV-1-positive plasma were significantly higher than those in healthy plasma. Unpaired t tests and Mann–Whitney U-tests were performed, p < 0.05 indicates significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4225041&req=5

Fig4: In vitrohepatitis C virus particle degradation experiment. Changes in the degradation dynamics of HCV-RNA and HCV- coreAg, (A) in medium, HIV-1-positive, and healthy plasma after incubation at 37°C for 12 hours. The X axis indicates the degradation of HCV-RNA or HCV-coreAg at 12 hours, expressed as a percentage of the initial levels. (B) HCV-coreAg/HCV-RNA ratios at 12 hours in HIV-1-positive plasma were significantly higher than those in healthy plasma. Unpaired t tests and Mann–Whitney U-tests were performed, p < 0.05 indicates significance.
Mentions: After incubating at 37°C for 12 hours, the average HCV-RNA levels decreased to 33.49%, 54.92%, and 73.16% of the initial levels in medium, healthy plasma, and HIV-1-positive plasma, respectively, whereas at the same time, the average HCV-coreAg levels decreased to 9.16%, 46.16%, and 42.45% of the initial levels. Decay rates of HCV-RNA and HCV-coreAg at 12 hours were significantly lower in medium than in healthy plasma (HCV-RNA: p < 0.001, HCV-coreAg: p < 0.001) and in HIV-1-positive plasma (HCV-RNA: p < 0.001, HCV-coreAg: p < 0.001) (Figure 4A). The decay rate of HCV-RNA in healthy plasma was significantly lower than in HIV-1-positive plasma (p = 0.035), while no similar difference was observed in the decay of HCV-coreAg (p > 0.05). Further, we observed that the Ag/RNA ratios in HIV-1-positive plasma were significantly higher than in healthy plasma (p = 0.005, Figure 4B). Certainly, it must be noted that the influence of blood cells on degradation of HCV is not addressed in this in vitro experiment.Figure 4

Bottom Line: Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012).An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study.Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.

View Article: PubMed Central - PubMed

ABSTRACT

Background: The measurement of hepatitis C virus core antigen (HCV-coreAg) has been shown to be an indicator of active HCV infection. The aim of the present study was 1) to investigate the stability and effectiveness of HCV-coreAg and HCV-RNA quantification in HCV infection with or without HIV-1 coinfection, 2) to explore the association between the HCV-coreAg/HCV-RNA (Ag/RNA) ratio and the immune status in chronic HCV/HIV-1-coinfected patients.

Methods: A longitudinal investigation comprised of 227 HCV-monoinfected (n = 129) and HCV/HIV-1-coinfected (n = 98) patients was initiated in August 2009, and 139 (73 with HCV monoinfection and 66 with HCV/HIV-1 coinfection) were followed up in August 2012. Both HCV core antigen and HCV RNA quantification were determined on this cryopreserved plasma. HCV core antigen and HCV RNA quantification were performed subsequently. In addition, an in vitro experiment investigating the possibility of degradation of HCV components (core antigen and RNA) were conducted.

Results: Significant and stable correlations (p < 0.001) were observed both in chronic HCV-monoinfected and HCV/HIV-1-coinfected patients over the 3-year observation. Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012). Moreover, the Ag/RNA ratios were negatively correlated with CD4+ T-cell counts (p < 0.001). An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study.

Conclusions: Our longitudinal study indicated that the HCV-coreAg presented comparable dynamics over time as HCV RNA in chronic HCV-infected patients. Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.

Show MeSH
Related in: MedlinePlus